After years of anticipation, the Food and Drug Administration will hold a public, two-day meeting starting on Wednesday to review the extent to which so-called off-label information about medicines may be disseminated to physicians.
Nothing will get decided, though. The meeting is designed simply to give the public — drug makers and patient advocates alike — a long-awaited chance to convey their opinions and debate the issue.
Off-label information refers to materials that describe unapproved uses of a drug. Doctors are allowed to prescribe a medicine for an unapproved use, but drug makers have long battled restrictions on their ability to distribute this type of information — such as reprints of medical studies — and have lobbied Congress and the FDA to loosen regulations.
About the Author Reprints
This might be part of the push for off label in AZ and then the rest of us:
http://www.esquire.com/lifestyle/health/a54160/big-pharma-against-legal-weed/?src=nl&mag=esq&list=nl_enl_news&date=032917